Chinese Japanese Germany


Antitumor drugs Preparation Anti-cancer drug Vorinostat was able to clear latent HIV virus
Chemical Name:
MK0683;SAHA cpd;orinostat;Vornostat;CCRIS 8456;Vorinostat;VoriNAstat;SAHA, >=99%;UNII-58IFB293JI;Vorinostat/SAHA
Molecular Formula:
Formula Weight:
MOL File:

Vorinostat Properties

Melting point:
storage temp. 
-20°C Freezer
DMSO: ≥15mg/mL
white to tan
CAS DataBase Reference
149647-78-9(CAS DataBase Reference)
  • Risk and Safety Statements
  • Hazard and Precautionary Statements (GHS)
Hazard Codes  T
Risk Statements  61-68
Safety Statements  53-36/37-45
WGK Germany  3
HS Code  29280000
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H341 Suspected of causing genetic defects Germ cell mutagenicity Category 2 Warning P201,P202, P281, P308+P313, P405,P501
H360 May damage fertility or the unborn child Reproductive toxicity Category 1A, 1B Danger
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P281 Use personal protective equipment as required.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P405 Store locked up.

Vorinostat price More Price(10)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich SML0061 SAHA ≥98% (HPLC) 149647-78-9 5mg $74.1 2018-11-13 Buy
Sigma-Aldrich SML0061 SAHA ≥98% (HPLC) 149647-78-9 25mg $300 2018-11-13 Buy
TCI Chemical H1388 N-Hydroxy-N'-phenyloctanediamide >98.0%(HPLC)(N) 149647-78-9 200mg $203 2018-11-22 Buy
Alfa Aesar H37305 Vorinostat 98% 149647-78-9 250mg $126 2018-11-20 Buy
Alfa Aesar H37305 Vorinostat 98% 149647-78-9 1g $291 2018-11-20 Buy

Vorinostat Chemical Properties,Uses,Production

Antitumor drugs

Vorinostat is a novel, molecularly targeted antineoplastic agent that causes cell cycle arrest and/or apoptosis by inhibiting histone deacetylase (HDAC). It is the first HDAC inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) with significant skin involvement that is still progressing, resistant or relapsing after two systemic regimens.
On October 6, 2006, the US Food and Drug Administration (FDA) have approved vorinostat capsules (vorinostat) for the treatment of skin cancer drugs. The drug is the first novel type of anti-cancer drugs of histone deacetylase inhibitor developed by the United States Merck for the treatment of skin T cell lymphoma (CTCL). FDA has approved it for the treatment of metastatic skin T-cell lymphoma which is unable to be cured or even worsened or gets recurrent cases. A large number of experimental studies and clinical results have shown that vorinostat has a excellent efficacy on a variety of tumors and have significant synergies when combined with other oncology drugs. The current treatment of other tumors is still undergoing in-depth study; these results show that vorinostat has a broad market prospects.
Vorinostat has low toxicity with the evidence of its safety and efficacy being supported by two clinical trials, including 107 patients with CTCL who had gotten relapsed after receiving other drugs. According to the standard analysis of improvement in the grade of skin lesion, 30% of patients treated with Zolinza get symptoms improved, with the average efficacy duration of 168 days. The most common serious adverse events were pulmonary embolism, dehydration, deep venous thrombosis and anemia. Common adverse reactions are gastrointestinal symptoms (including diarrhea, nausea and loss of appetite, vomiting and constipation); fatigue, chills and taste disorders. Animal experiments showed that pregnant women should be banned of using the drug.


Suberic acid can undergo the intramolecular dehydration into suberic anhydride under the action of the acetic anhydride. The suberic anhydride, together with aniline can have ring-opening amidation in ethyl acetate at 0 °C to generate suberic acid monoanilide, followed by methanol esterification and hydroxylamine amine aminolysis to obtain the anti-tumor drug in vorinostat with the total yield of about 65%.
"Chinese Journal of Pharmaceutical Industry" 2009, Volume 40, No. 7, pages 481-483

Anti-cancer drug Vorinostat was able to clear latent HIV virus

Researchers from the University of North Carolina at Chapel Hill have published a groundbreaking research paper in the July 25, 2012 issue of Nature to confirm that a deacetylase inhibitor drug – vorinostat that can be used to treat certain types of lymphoma-being capable of clearing out the patient's latent HIV virus in vivo.
The researchers have conducted a series of experiments to evaluate the potential of this drug to activate and destroy latent HIV viruses. Initially, laboratory experiments for measuring the level of active HIV in CD4 + T cells showed that vorinostat can take off the camouflage of latent HIV viruses in these cells. Then, eight male patients who still kept medically stable HIV infection after antiretroviral therapy, took vorinostat, and then were tested their active HIV levels in the body and compared it to the levels they had before taking the drug.
The researchers found that HIV-RNA levels in CD4 + T cells increased by an average of 4.5-fold in those patients who receiving vorinostat, confirming that the HIV virus was disguised. This is the first published study confirming that deacetylase inhibitors have the potential to break down latency in latent virus libraries. The study provides convincing evidence that a new strategy may be used to directly attack and eradicate latent HIV infection. However, getting rid of the latent nature of HIV is only the first step in curing HIV infection.

Chemical Properties

White Crystalline Solid


A potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Induces differentiation in uman breast cancer cells.


antineoplastic, histone deacetylase inhibitor


Suberoylanilide Hydroxamic Acid is a potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Suberoylanilide Hydroxamic Acid displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Suberoylanilide Hydroxamic Acid induces differentiation in uman breast cancer cells.


A potent HDAC inhibitor; also causes cell cycle arrest at G1


ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Vorinostat Preparation Products And Raw materials

Raw materials

Preparation Products

Vorinostat Suppliers

Global( 223)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3217 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22058 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20795 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32763 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070; CHINA 3015 60
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 CHINA 893 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 14297 60
08657186217390 CHINA 301 58
Jinan Jianfeng Chemical Co., Ltd
15562555968 CHINA 617 58
0086-13720134139 CHINA 956 58

View Lastest Price from Vorinostat manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-12-24 Vorinostat
US $2.00 / kg 1kg 99% 100kg career henan chemical co

149647-78-9(Vorinostat)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved